Corrigendum to Circulating miR-122-5p/miR-133b ratio is a specific early prognostic biomarker in acute myocardial infarction (Circulation Journal, (2016) 80:10, (2183-91), 10.1253/circj.CJ-16-0568);Circulating miR-122-5p/miR-133B ratio is a specific early prognostic biomarker in acute myocardial infarction

Circulation Journal

Volumn 80, Issue 10, 2016, Pages 2183-2191

  Cortez Dias, Nuno ^a,b   Costa, Marina C ^c   Carrilho Ferreira, Pedro ^a   Silva, Doroteia ^a   Jorge, Cláudia ^a   Calisto, Carina ^a   Pessoa, Teresa ^a   Martins, Susana Robalo ^a   de Sousa, João Carvalho ^a   da Silva, Pedro Canas ^a   Fiúza, Manuela ^a   Diogo, António Nunes ^a   Pinto, Fausto J ^a   Enguita, Francisco J ^c  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b Ministerio da Saude Portuguese   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Circulating miRNAs; miR 122 5p; miR 133b; Myocardial infarction; Risk stratification

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE; CREATINE KINASE MB; GAMMA GLUTAMYLTRANSFERASE; MICRORNA; MICRORNA 1; MICRORNA 122; MICRORNA 133A; MICRORNA 133B; MICRORNA 208; MICRORNA 499A; TROPONIN I; UNCLASSIFIED DRUG; UREA; URIC ACID; MIRN122 MICRORNA, HUMAN; MIRN133 MICRORNA, HUMAN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; ENZYME IMMUNOASSAY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TRANSTHORACIC ECHOCARDIOGRAPHY; UNSTABLE ANGINA PECTORIS; AGED; BLOOD; CLINICAL TRIAL; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDY; ST ELEVATION MYOCARDIAL INFARCTION;

AGED; BIOMARKERS; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; ST ELEVATION MYOCARDIAL INFARCTION;

EID: 84988556587     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-66-0140     Document Type: Erratum

References (38)

1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854.
2. Quiat D, Olson EN. MicroRNAs in cardiovascular disease: From pathogenesis to prevention and treatment. J Clin Invest 2013; 123: 11-18.
3. De Rosa S, Curcio A, Indolfi C. Emerging role of microRNAs in cardiovascular diseases. Circ J 2014; 78: 567-575.
4. Fukushima Y, Nakanishi M, Nonogi H, Goto Y, Iwai N. Assessment of plasma miRNAs in congestive heart failure. Circ J 2011; 75: 336-340.
5. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-10518.
6. Hata S. Need and importance of biomarkers to predict acute myocardial infarction and its prognosis. Circ J 2012; 76: 2090-2091.
7. Adachi T, Nakanishi M, Otsuka Y, Nishimura K, Hirokawa G, Goto Y, et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin Chem 2010; 56: 1183-1185.
8. Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010; 391: 73-77.
9. Cheng Y, Tan N, Yang J, Liu X, Cao X, He P, et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci (Lond) 2010; 119: 87-95.
10. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 2010; 3: 499-506.
11. D’Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010; 31: 2765-2773.
12. Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 2011; 4: 446-454.
13. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, et al. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010; 31: 659-666.
14. Devaux Y, Vausort M, Goretti E, Nazarov PV, Azuaje F, Gilson G, et al. Use of circulating microRNAs to diagnose acute myocardial infarction. Clin Chem 2012; 58: 559-567.
15. Eitel I, Adams V, Dieterich P, Fuernau G, de Waha S, Desch S, et al. Relation of circulating microRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction. Am Heart J 2012; 164: 706-714.
16. Gidlof O, Smith JG, Miyazu K, Gilje P, Spencer A, Blomquist S, et al. Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovasc Disord 2013; 13: 12.
17. Zhang R, Niu H, Ban T, Xu L, Li Y, Wang N, et al. Elevated plasma microRNA-1 predicts heart failure after acute myocardial infarction. Int J Cardiol 2013; 166: 259-260.
18. Devaux Y, Vausort M, McCann GP, Kelly D, Collignon O, Ng LL, et al. A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction. PLoS One 2013; 8: e70644, doi:10.1371/journal.pone.0070644.
19. Matsumoto S, Sakata Y, Nakatani D, Suna S, Mizuno H, Shimizu M, et al. A subset of circulating microRNAs are predictive for cardiac death after discharge for acute myocardial infarction. Biochem Biophys Res Commun 2012; 427: 280-284.
20. Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012; 60: 290-299.
21. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87-98.
22. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452: 896-899.
23. Gao W, He HW, Wang ZM, Zhao H, Lian XQ, Wang YS, et al. Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis 2012; 11: 55.
24. Andersson P, Gidlof O, Braun OO, Gotberg M, van der Pals J, Olde B, et al. Plasma levels of liver-specific miR-122 is massively increased in a porcine cardiogenic shock model and attenuated by hypothermia. Shock 2012; 37: 234-238.
25. Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X, et al. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 2009; 284: 29514-29525.
26. Huang X, Huang F, Yang D, Dong F, Shi X, Wang H, et al. Expression of microRNA-122 contributes to apoptosis in h9c2 myocytes. J Cell Mol Med 2012; 16: 2637-2646.
27. Bostjancic E, Zidar N, Glavac D. MicroRNAs and cardiac sarcoplasmic reticulum calcium ATPase-2 in human myocardial infarction: Expression and bioinformatic analysis. BMC Genomics 2012; 13: 552.
28. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 2011; 108: 3713-3718.
29. Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, et al. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 2011; 106: 13-23.
30. Goretti E, Vausort M, Wagner DR, Devaux Y. Association between circulating microRNAs, cardiovascular risk factors and outcome in patients with acute myocardial infarction. Int J Cardiol 2013; 168: 4548-4550.
31. Liebetrau C, Mollmann H, Dorr O, Szardien S, Troidl C, Willmer M, et al. Release kinetics of circulating muscle-enriched microRNAs in patients undergoing transcoronary ablation of septal hypertrophy. J Am Coll Cardiol 2013; 62: 992-998.
32. Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 2011; 51: 872-875.
33. Kaudewitz D, Lee R, Willeit P, McGregor R, Markus HS, Kiechl S, et al. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb Haemost 2013; 110: 609-615.
34. Bauters C, Kumarswamy R, Holzmann A, Bretthauer J, Anker SD, Pinet F, et al. Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int J Cardiol 2013; 168: 1837-1840.
35. Wei T, Folkersen L, Ehrenborg E, Gabrielsen A. MicroRNA 486-3p as a stability marker in acute coronary syndrome. Biosci Rep 2016; 36: e00351, doi:10.1042/BSR20160023.
36. Matsumoto S, Sakata Y, Suna S, Nakatani D, Usami M, Hara M, et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ Res 2013; 113: 322-326.
37. Chiam K, Wang T, Watson DI, Mayne GC, Irvine TS, Bright T, et al. Circulating serum exosomal miRNAs as potential biomarkers for esophageal adenocarcinoma. J Gastrointest Surg 2015; 19: 1208-1215.
38. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011; 108: 5003-5008.